TOP HEADLINES

FEATURED STORY

  • WuXi's CEO moves to take the CRO private

    WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.

Quintiles' founders bank $770M in secondary offering

A group of Quintiles shareholders including the CRO's founder made about $770 million in a secondary stock offering, selling a bulk of shares back to the company and cashing in on its success.

Quotient Clinical soars in its first year after a PE buyout

A year removed from taking a private equity buyout, U.K. CRO Quotient Clinical has watched demand for its services spike, the company said, plotting some major investments to keep the pace of growth.

InVentiv invests in compliance as regulations shift for real-world studies

CRO inVentiv Health is amping up its capacity in regulatory compliance to prepare for changes in European trial rules, unveiling a global database it claims can help sponsors avoid costly confusion.

WuXi posts another big quarter as it faces a big decision

WuXi PharmaTech, China's largest CRO, again boosted its revenue by double digits last quarter, keeping the pace of growth as it considers an offer to go private.

Patheon sells off its Mexican division for $34M

Contract drug developer Patheon has flipped its Mexican operations to Perrigo for $34 million in cash, shifting its focus to the U.S. and Europe.

MORE NEWS

From Our Sister Sites

FierceBiotech

In this week's EuroBiotech Report, Abivax became the latest French biotech to file for an IPO in its home country, seeking cash ahead of moving an HIV drug into two Phase IIb trials, as well as to support the clinical development of its lead candidate, a therapeutic vaccine against hepatitis B. And more.

FierceBiotech

The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $116 million.